Literature DB >> 30238018

Solitary Extrahepatic Intramuscular Metastasis from Cryptogenic Hepatocellular Carcinoma.

Talhah Zubair1, Timothy Yen2, Gordon Gao3.   

Abstract

Although hepatocellular carcinoma (HCC) recurrence after curative resection is not uncommon, it primarily recurs in the liver prior to metastatic progression. We report a case of resected pT2N0 cryptogenic HCC that recurred in the superior paracervical musculature without evident intrahepatic recurrence. The patient also developed cervical spine instability requiring urgent neurosurgery. Cryptogenic HCC is thought to arise from non-alcoholic fatty liver disease even without cirrhosis. Unfortunately, it also portends a worse prognosis compared to HCC of other etiologies. This highlights the aggressive behavior of cryptogenic HCC, which warrants further research as non-alcoholic fatty liver disease becomes increasingly common.

Entities:  

Year:  2018        PMID: 30238018      PMCID: PMC6137291          DOI: 10.14309/crj.2018.64

Source DB:  PubMed          Journal:  ACG Case Rep J        ISSN: 2326-3253


Introduction

It is not uncommon for hepatocellular carcinoma (HCC) to recur after curative resection. When it does recur, there is usually recurrence of the primary intrahepatic tumor. Any additional extrahepatic recurrences most often present in the lungs (39.5%) and lymph nodes (34.2%), with rare presentation in musculature.1

Case Report

A 71-year-old man with a history of localized prostate cancer (cT1c, Gleason 3  +  3) and localized melanoma status post excision presented with right upper quadrant abdominal pain. A hepatic mass suspicious for HCC was found on imaging. He subsequently received a hepatic wedge resection with cholecystectomy and portocaval lymph node dissection. Pathologic staging was determined at pT2N0, and the 3.9-cm tumor was a well to moderately differentiated HCC with a 1.8-cm margin and evidence of microvascular invasion but no involvement of macroscopic portal or hepatic veins, gallbladder, or lymph nodes. As a result, the patient was staged at pT2N0. Of note, the non-neoplastic liver parenchyma was found to have moderate steatosis with grade 1 portal chronic inflammation and stage 1 portal fibrosis, thought to be a result of mass effect from the tumor. The patient had no evidence of iron overload on staining, did not drink alcohol regularly, and was serologically negative for hepatitis B, hepatitis C, Wilson’s, α-1 antitrypsin deficiency, and autoimmune hepatitis. One year after resection, the patient presented to the emergency department with 3 months of progressive left-sided neck pain after a car accident. On presentation, his labs showed α-fetoprotein of 139.8 μg/L (from 32.6 μg/L at 4 months prior) and a prostate-specific antigen of 11.51 ng/mL (from 8.86 ng/mL at 4 months prior). All other labs were within normal limits, including liver function tests. Of note, a recent triphasic computerized tomography (CT) abdomen done for routine biannual surveillance showed no HCC. Given the persistence of his symptoms, he underwent a neck CT in the emergency department, which showed a 5 × 4 × 4 cm heterogeneously enhancing mass centered in the left paraspinal musculature of the craniocervical junction. The mass encased the vertebral artery, internal jugular vein, and lateral process of the C1 vertebra, for which he eventually required neurosurgical intervention due to atlantoaxial instability (Figure 1). A full-body positron emission tomography scan, ordered due to his history of multiple malignancies, revealed no additional hypermetabolic masses. Subsequent CT-guided biopsy of the neck mass showed poorly differentiated clusters of malignant cells with enlarged pleomorphic nuclei, irregular nuclear contours, and a moderate amount of granular-to-vacuolated cytoplasm. Immunohistochemistry showed that the cells were positive for HepPar-1 and focally positive for arginase-1, supporting a diagnosis of metastatic HCC.2
Figure 1

Mass encasing the vertebral artery, internal jugular vein, and lateral process of the C1 vertebra.

Mass encasing the vertebral artery, internal jugular vein, and lateral process of the C1 vertebra.

Discussion

The recurrence rate of HCC after resection is estimated to be around 70% within 5 years of surgery. However, one series of 348 HCC resections showed that only 3.4% of patients had extrahepatic recurrence without intrahepatic lesions.3 Furthermore, the site of our patient’s metastasis was fairly rare, located in the high-risk musculature surrounding the superior cervical spine.4 The hypothesized route for such paraspinal metastases is through Batson’s plexus connecting the azygos vein, hemiazygos vein, and vertebral venous plexus. Although this patient initially had resectable disease, the presence of microvascular invasion on pathology from his hepatic wedge resection suggests a plausible mechanism for his subsequent solitary metastasis. Furthermore, our patient had no clear etiology of HCC except for moderate non-alcoholic steatosis noted on biopsy, with only mild portal inflammation and fibrosis thought to be related to tumor mass effect. In fact, non-alcoholic fatty liver disease (including steatohepatitis) is thought to be theetiology of most cryptogenic HCC, even in the absence of significant fibrosis or cirrhosis.5 One theory of interest hypothesizes that hepatocellular adenomas are the precursor lesion, particularly in patients with both fatty liver disease and metabolic syndrome.6 Unfortunately, these patients also tend to present with larger tumors and more advanced stages of disease, and they have poorer overall survival.7 Given the paucity of data, current guidelines for post-resection surveillance for HCC of any etiology recommend α-fetoprotein and cross-sectional abdominal imaging every 3–4 months for 3 years, and every 6 months thereafter.8 Although our patient received appropriate surveillance imaging after resection, he clearly had a poor outcome with a fairly rapid progression from initial diagnosis of resectable HCC to aggressively metastatic disease within 1 year. With the growing prevalence of non-alcoholic fatty liver disease, this case report highlights the importance of further research into cryptogenic HCC.9,10

Disclosures

Author contributions: T. Zubair wrote the manuscript. T. Yen and G. Gao edited and supervised the manuscript. T. Yen is the article guarantor. Financial disclosure: None to report. Informed consent was obtained for this case report.
  10 in total

1.  Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.

Authors:  Judith Ertle; Alexander Dechêne; Jan-Peter Sowa; Volker Penndorf; Kerstin Herzer; Gernot Kaiser; Jörg F Schlaak; Guido Gerken; Wing-Kin Syn; Ali Canbay
Journal:  Int J Cancer       Date:  2011-03-14       Impact factor: 7.396

Review 2.  Treatment options and surveillance strategies after therapy for hepatocellular carcinoma.

Authors:  Ioannis Hatzaras; Danielle A Bischof; Bridget Fahy; David Cosgrove; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2013-09-05       Impact factor: 5.344

3.  More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma.

Authors:  Tomi W Jun; Ming-Lun Yeh; Ju Dong Yang; Vincent L Chen; Pauline Nguyen; Nasra H Giama; Chung-Feng Huang; Ann W Hsing; Chia-Yen Dai; Jee-Fu Huang; Wan-Long Chuang; Lewis R Roberts; Ming-Lung Yu; Mindie H Nguyen
Journal:  Liver Int       Date:  2017-11-03       Impact factor: 5.828

4.  Changing trends in malignant transformation of hepatocellular adenoma.

Authors:  Olivier Farges; Nelio Ferreira; Safi Dokmak; Jacques Belghiti; Pierre Bedossa; Valérie Paradis
Journal:  Gut       Date:  2011-01       Impact factor: 23.059

5.  Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection.

Authors:  Yubo Yang; Hiroaki Nagano; Hideo Ota; Osakuni Morimoto; Masato Nakamura; Hiroshi Wada; Takehiro Noda; Bazarragchaa Damdinsuren; Shigeru Marubashi; Atsushi Miyamoto; Yutaka Takeda; Keizo Dono; Koji Umeshita; Shoji Nakamori; Kenichi Wakasa; Masato Sakon; Morito Monden
Journal:  Surgery       Date:  2007-02       Impact factor: 3.982

6.  Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors.

Authors:  Koji Uchino; Ryosuke Tateishi; Shuichiro Shiina; Miho Kanda; Ryota Masuzaki; Yuji Kondo; Tadashi Goto; Masao Omata; Haruhiko Yoshida; Kazuhiko Koike
Journal:  Cancer       Date:  2011-03-22       Impact factor: 6.860

7.  Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens.

Authors:  Dana T Timek; Jianhui Shi; Haiyan Liu; Fan Lin
Journal:  Am J Clin Pathol       Date:  2012-08       Impact factor: 2.493

8.  Extrahepatic metastasis of hepatocellular carcinoma to the paravertebral muscle: A case report.

Authors:  Kazuhiro Takahashi; Krishna G Putchakayala; Mohamed Safwan; Dean Y Kim
Journal:  World J Hepatol       Date:  2017-08-08

Review 9.  Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma.

Authors:  Adnan Said; Aiman Ghufran
Journal:  World J Clin Oncol       Date:  2017-12-10

Review 10.  Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management.

Authors:  George Cholankeril; Ronak Patel; Sandeep Khurana; Sanjaya K Satapathy
Journal:  World J Hepatol       Date:  2017-04-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.